Cambridge, UK – 1 October 2025 – Biosceptre International Limited is pleased to announce the successful completion of its 2025 fundraise, securing £8.1 million through the issue of 40,500,000 new shares.
This achievement underscores the strong confidence of investors in Biosceptre’s pioneering approach to developing novel treatments for hard-to-treat cancers.
Biosceptre CEO Gavin Currie commented:
“This fundraise marks an important milestone for Biosceptre as we accelerate the development of our therapeutic pipeline. With the continued support of our investors, we are advancing towards our vision of bringing transformative treatments to patients worldwide. Our team is deeply committed to tackling some of the most pressing challenges in oncology and to building a future where patients have access to more effective and targeted therapies.”
With this new capital in place, Biosceptre will continue to progress its therapeutic pipeline and deliver on key milestones in the months ahead.
The newly issued shares are scheduled to be dispatched by 8th October 2025.
For further information, please contact:
Investor Relations
info@biosceptre.com